Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.55 |
| ▸ | JAK3 | P52333 | 20/20 | 0.55 |
| ▸ | JAK2 | O60674 | 10/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346388 | 0.87 | JAK1 (0.52) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL29752260 | 0.87 | JAK1 (0.58) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL17236302 | 0.84 | JAK1 (0.60) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL29609671 | 0.83 | JAK1 (0.60) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL19975657 | 0.83 | JAK1 (0.60) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL524757 | 0.83 | JAK1 (0.60) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL341705 | 0.83 | JAK1 (0.49) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL2990449 | 0.83 | JAK1 (0.61) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL341026 | 0.82 | JAK1 (0.59) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL525125 | 0.82 | JAK1 (0.59) | JAK1JAK3JAK2CYP1A2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019040706-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO | ACLARIS THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |